---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-031039"
form_type: "8-K"
ticker: "MASS"
cik: "0001555279"
company_name: "908 Devices Inc."
filed_at: "2022-03-07T23:59:59+00:00"
generated_at: "2026-06-27T01:09:21.660338+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# 908 Devices Q4 rev $15.8M (+177% YoY); net loss $3.5M; FY22 guide $52-55M

## Summary
- Full-year 2021 revenue $42.2M (+57% YoY); net loss $22.2M ($0.79 loss per share).
- Q4 gross margin improved to 58% from 49%; installed base expanded to 1,935 devices.
- Cash $224M at year-end; debt outstanding $15M.
- FY 2022 revenue outlook $52M-$55M, representing 23%-30% growth over FY 2021.
- Commercial traction with all top 20 biopharma; Tony Hunt (Repligen CEO) added to board.

## SEC filing metadata
- accession: 0001104659-22-031039
- form_type: 8-K
- ticker: MASS
- cik: 0001555279
- company_name: 908 Devices Inc.
- filed_at: 2022-03-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1555279/000110465922031039/0001104659-22-031039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1555279/000110465922031039/tm228482d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-031039
- JSON: https://secwatch.observer/filing/0001104659-22-031039.json
- Plain text: https://secwatch.observer/filing/0001104659-22-031039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.